Are androgen receptor variants a substitute for the full-length receptor?

Nature Reviews Urology

Volumn 12, Issue 3, 2015, Pages 137-144

  Lu, Ji ^a   Der Steen, Travis Van ^b   Tindall, Donald J ^c  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b DEPARTMENT OF UROLOGY   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ASC J 9; DOCETAXEL; ENZALUTAMIDE; EPI 001; EPI 002; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; MAHANINE; MORPHOLINE DERIVATIVE; NICLOSAMIDE; PYRVINIUM EMBONATE; UNCLASSIFIED DRUG; ISOPROTEIN;

ALTERNATIVE RNA SPLICING; ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; DRUG SCREENING; EXON; GENE EXPRESSION; GENE LOCUS; GENETIC VARIABILITY; HORMONE RESPONSIVE ELEMENT; HUMAN; LIGAND BINDING; LNCAP CELL LINE; MOLECULARLY TARGETED THERAPY; MURRAYA KOENIGII; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN PROTEIN INTERACTION; RECEPTOR GENE; REVIEW; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NEOPLASM; PHYSIOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84924533221     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2015.13     Document Type: Review

References (68)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
2. Attard, G., Cooper, C. S. & de Bono, J. S. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16, 458-462 (2009).
3. Deb es, J. D. & Tindall, D. J. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351, 1488-1490 (2004).
4. Feldman, B. J. & Feldman, D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45 (2001).
5. Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39 (2004).
6. Hein lein, C. A. & Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 25, 276-308 (2004).
7. Gottlieb, B., Beitel, L. K., Nadarajah, A., Paliouras, M. & Trifiro, M. The androgen receptor gene mutations database: 2012 update. Hum. Mutat. 33, 887-894 (2012).
8. Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447-4454 (2008).
9. Locke, J. A. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68, 6407-6415 (2008).
10. Buchanan, G., Irvine, R. A., Coetzee, G. A. & Tilley, W. D. Contribution of the androgen receptor to prostate cancer predisposition and progress ion. Cancer Metastasis Rev. 20, 207-223 (2001).
11. Heemers, H. V. & Tindall, D. J. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional c omplex. Endocr. Rev. 28, 778-808 (2007).
12. van der Steen, T., Tindall, D. J. & Huang, H. Posttranslational modification of the androgen receptor in prostate cancer. Int. J. Mol. Sci. 14, 14833-14859 (2013).
13. Bain D. L.,Heneghan A. F.,Connaghan-Jones K. D.,Miura M. T Nuclear receptor structure: implications for function. Annu. Rev. Physiol 69 201-220 2007).
14. Dehm, S. M. & Tindall, D. J. Alternatively spliced androgen receptor variants. Endocr. Relat Cancer 18, R183-R196 (2011).
15. Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L. & Tindall, D. J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resist ance. Cancer Res. 68, 5469-5477 (2008).
16. Guo, Z. et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69, 2305-2313 (2009).
17. Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16-22 (2009).
18. Sun, S. et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120, 2715-2730 (2010).
19. Watson, P. A. et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl Acad. Sci. USA 107, 16759-16765 (2010).
20. Marcias, G. et al. Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum. Mutat. 31, 74-80 (2010).
21. Hu, R., Isa acs, W. B. & Luo, J. A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71, 1656-1667 (2011).
22. Yang, X. et al. Novel membrane-Associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. J. Biol. Chem. 286, 36152-36160 (2011).
23. Jagla, M. e t al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology 148, 4334-4343 (2007).
24. Ceraline, J. et al. Cons titutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int. J. Cancer 108, 152-157 (2004).
25. Hu, D. G. et a l. Identification of Androgen Receptor Splice Variant Transcripts in Breast Cancer Cell Lines and Human Tissues. Horm. Cancer 5, 61-71 (2014).
26. Libertini, S. J. et al. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res. 67, 9001-9005 (2007).
27. Chen, H. et al. ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell lines. J. Biol. Chem. 285, 2368-2374 (2010).
28. Li, Y. et al. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Res. 71, 2108-2117 (2011).
29. Li, Y. et al. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene 31, 4759-4767 (2012).
30. Nyquist, M. D. et al. TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc. Natl Acad. Sci. USA 110, 17492-17497 (2013).
31. Liu, L. L. et al. Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 33, 3140-3150 (2014).
32. Yu, Z. et al. Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer. Clin. Cancer Res. 20, 1590-1600 (2014).
33. Bitting, R. L., Schaeffer, D., Somarelli, J. A., Garcia-Blanco, M. A. & Armstrong, A. J. The role of epithelial plast icity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev. 33, 441-468 (2014).
34. Cottard F.,et al Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells PLoS ONE 8, e63466 2013).
35. Liu, G. et al. AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia 15, 1009-1017 (2013).
36. Sun, F. et al. Androgen Receptor Splice Variant AR3 Promotes Prostate Cancer via Modulating Expression of Autocrine/Paracrine Factors. J. Biol. Chem. 289, 1529-1539 (2014).
37. Mostaghel, E. A. et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Canc er Res. 17, 5913-5925 (2011).
38. Li, Y. et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 73, 483-489 (2013).
39. Cao, B. et al. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5, 1646-1656 (2014).
40. Hornberg, E. et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 6, e19059 (2011).
41. Zhang, X. et al. Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS ONE 6, http://dx.doi.org/10.1371/journal.pone.0027970 (2011).
42. Zhao, H. et al. Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression. J. Urol. 188, 2158-2164 (2012).
43. Antonarakis, E. S. et al. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. N. Engl. J. Med. 371, 1028-1038 (2014).
44. Smith, D. F. & Toft, D. O. Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. Mol. Endocrinol. 22, 2229-2240 (2008).
45. Cardillo , M. R. & Ippoliti, F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-Assisted image analysis. Anticancer Res. 26, 3409-3416 (2006).
46. O'Malley, K. J. et al. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. Prostate 72, 1117-1123 (2012).
47. Centenera, M. M. et al. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin. Cancer Res. 18, 3562-3570 (2012).
48. Gillis, J. L. et al. Constitutively-Active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. Oncotarget 4, 691-704 (2013).
49. Shafi, A. A., Cox, M. B. & Weigel, N. L. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids 78, 548-554 (2013).
50. Thadani-Mulero, M. et al. Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer. Cancer Res. 74, 2270-2282 (2014).
51. Hu, R. et al. Distinct transcriptional programs mediated by the ligand-dependent full-lengt h androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 72, 3457-3462 (2012).
52. Lu, J. et al. The cistrome and gene signature of androgen receptor splice variants in castration-resistant prostate cancer cells. J. Urol. http://dx.doi.org/10.1016/j.juro.2014.08.043 (2014).
53. Chmelar, R., Buchanan, G., Need, E. F., Tilley, W. & Greenberg, N. M. Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer 120, 719-733 (2007).
54. Streicher, W. et al. AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells. World J. Urol. 30, 333-339 (2012).
55. Andersen, R. J. et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17, 535-546 (2010).
56. Myung J. K.,et al An androgen receptor N-terminal domain antagonist for treating prostate cancer. J. Clin. Invest 123 2948-2960, 2013).
57. Bohrer, L. R. et al. FOXO1 b inds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants. Prostate 73, 1017-1027 (2013).
58. Lim, M. et al. Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium. ACS Chem. Biol. 9, 692-702 (2014).
59. Li, H. et al. Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor. J. Med. Chem. 57, 6458-6467 (2014).
60. Dalal, K. et al. Selectively Targeting the DNA Binding Domain of the Androgen Receptor as a Prospective Therapy for Prostate Cancer. J. Biol. Chem. http://dx. doi.org/10.1074/jbc.A114.553818 (2014).
61. Liu, C. et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin. Cancer Res. 20, 3198-3210 (2014).
62. Wu, K. et al. The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene 33, 1954-1963 (2014).
63. A min, K. S. et al. A naturally derived small molecule disrupts ligand-dependent and ligand-independent androgen receptor signaling in human prostate cancer cells. Mol. Cancer Ther. 13, 341-352 (2014).
64. Lai, K. P. et al. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am. J. Pathol. 182, 460-473 (2013).
65. Yamashita, S. et al. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 14, 74-83 (2012).
66. Stope, M. B. et al. Shortened isoforms of the androgen receptor are regulated by the cytoprotective heat-shock protein HSPB1 and the tumor-suppressive microRNA miR-1 in prostate cancer cells. Anticancer Res. 33, 4921-4926 (2013).
67. Peacock, S. O., Fahrenholtz, C. D. & Burnstein, K. L. Vav3 Enhances Androgen Receptor Splice Variant Activity and Is Critical for Castration-Resistant Prostate Cancer Growth and Survival. Mol. Endocr inol. 26, 1967-1979 (2012).
68. Nadiminty, N. et al. NF-kappaB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol. Cancer Ther. 12, 1629-1637 (2013).